# Oral Film Testing and Stability Planning | StripWorks Canonical source: https://stripworks.com/insights/oral-film-testing-stability-plan Description: Which tests release an oral strip lot, what ICH accelerated conditions actually tell you, the USP chapters that apply, and how to build a 24-month plan. published_at: 2026-07-13 modified_at: 2026-09-17 This is a text rendering of the public page, not a separate publication. Cite the canonical source. Commercial specifications, prices, claims and ingredient feasibility require project-specific confirmation. [Home](https://stripworks.com/) / [Insights](https://stripworks.com/insights/) / Oral Film Testing and Stability Planning STRIPWORKS INSIGHTS # Oral Film Testing and Stability Planning Which tests release an oral strip lot, what ICH accelerated conditions actually tell you, the USP chapters that apply, and how to build a 24-month plan. 10 MIN READ UPDATED SEP 17, 2026 PUBLISHED BY [STRIPWORKS](https://stripworks.com/about-stripworks) [EDITORIAL STANDARDS](https://stripworks.com/editorial-standards) ANSWER IN BRIEF Release testing answers "is this lot what the spec says"; stability answers "for how long." A strip release panel is appearance, dimensions and weight, moisture or water activity, seal and coding, potency, content uniformity where the dose matters, and micro. Shelf life comes from real-time data at 25 °C/60 % RH; the 40 °C/75 % RH study is an early-warning tool, not a substitute. Release panel for an oral strip and the chapter behind each test | Test | Reference | Typical limit or note | | --- | --- | --- | | Appearance, dimensions, weight | Spec | 22 × 32 mm; weight per unit against target | | Moisture or water activity | USP \<1112\> | Water activity below 0.60 blocks growth of all listed organisms | | Seal integrity and coding | Spec | Visual plus dye or vacuum leak on a sample | | Potency | Validated assay | Against label claim | | Content uniformity | USP \<905\> | AV ≤ 15.0 on 10 units; 30 units if needed | | Microbial limits | USP \<2021\>, \<2022\>, \<2023\> | TAMC ≤ 10³, TYMC ≤ 10² cfu/g; E. coli absent in 10 g (non-botanical) | | Disintegration | Method written in spec | 30 to 60 s target; USP \<701\> not suited to films | ## Release and shelf life are different questions A release specification is the lot's pass/fail list, tested before disposition. A stability protocol repeats those tests on stored samples at set pull points. Write both before the pilot is cast, with a method and a signer for each test. Our standard is the same core panel on every lot, third-party work through ILS Lab, and one Lot Release Packet per lot. ## The release panel and the chapters behind it Potency is an assay against label claim. Content uniformity follows USP \<905\>: ten units, acceptance value not more than 15.0, then thirty if the first ten miss. Micro for supplements is USP \<2021\> and \<2022\> judged against \<2023\>: TAMC ≤ 10³ cfu/g, TYMC ≤ 10² cfu/g, E. coli absent in 10 g for non-botanical products. ## Disintegration: the number nobody has standardized FDA's ODT guidance uses about 30 s in vitro as the benchmark; Ph. Eur. asks only that orodispersible films "disperse rapidly"; reviews use not more than 60 s. The USP \<701\> basket was built for tablets, and a 2019 comparison found it a poor predictor for films, while a cell method matched in-mouth times at R² = 0.999. Our target is 30 to 60 s. Write apparatus, medium, temperature, and endpoint into the spec or the number means nothing. ## What "accelerated" actually means ICH Q1A(R2) sets long-term at 25 °C ± 2 °C / 60 % RH ± 5 % for at least 12 months and accelerated at 40 °C ± 2 °C / 75 % RH ± 5 % for 6 months, pulled at 0, 3, and 6. A "significant change" there (a 5 % assay shift, a degradant over limit, or a failed physical or functional attribute) triggers an intermediate study at 30 °C / 65 % RH. Accelerated data support a provisional date; real-time pulls confirm the 24-month target we develop toward. ICH also notes moisture is not a concern in impermeable containers, which is the case for a foil sachet. ## Water activity as early warning USP \<1112\> lists what each organism needs: about 0.97 for Pseudomonas aeruginosa, 0.86 for Staphylococcus aureus, 0.77 for Aspergillus niger, 0.61 for the most xerophilic mold; below 0.60 nothing grows. A strip at 4 to 7 % moisture usually reads well under 0.60, and a rise across pull points is the first sign of a leaking sachet. ## Worked example: a 24-month plan for a melatonin strip A hypothetical brand, Harbor Sleep, wants "best by 24 months" on a 3 mg strip in foil. From the 15,000-strip pilot: 40 °C/75 % RH pulls at 0, 1, 3, 6 months; 25 °C/60 % RH at 0, 3, 6, 9, 12, 18, 24. Each pull: appearance, weight, water activity, disintegration, melatonin assay; micro at 0, 12, 24. Thirty sachets per pull over eleven pulls is 330 sachets, about 2 % of the lot. Limits: assay 90 to 110 %, water activity ≤ 0.60, disintegration ≤ 60 s, no seal failure. A clean 6-month accelerated result supports a 12-month provisional date; the 24-month claim waits for the 24-month pull. ## Questions for the manufacturer Which tests are in the panel and which cost extra. Who chooses methods. Who pays for repeats and how an out-of-spec result is investigated. What arrives with the lot. Who stores stability samples and is responsible for the pull calendar. ## Common questions **Can a 6-month accelerated study justify a 24-month date?** Not on its own. It supports a provisional date and flags problems early. Real-time data at 25 °C/60 % RH confirm the claim. **How many batches do we need on stability?** ICH asks for three primary batches for a drug application. For a supplement pilot, one lot on a full protocol is a defensible start, with each later lot added at a reduced pull schedule. ## Primary sources - [ICH Q1A(R2) Stability Testing of New Drug Substances and Products](https://database.ich.org/sites/default/files/Q1A(R2%29%20Guideline.pdf) - [FDA Guidance for Industry: Orally Disintegrating Tablets (2008)](https://www.fda.gov/media/70877/download) - [Disintegration time of orally dissolving films: methodologies and in-vitro/in-vivo correlation (Pharmazie, 2019)](https://pubmed.ncbi.nlm.nih.gov/30940306/) - [Orodispersible Films: Current Innovations and Emerging Trends (Pharmaceutics, 2023, PMC10747242)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10747242/) - [USP \<1112\> Application of Water Activity Determination to Nonsterile Pharmaceutical Products](https://www.drugfuture.com/pharmacopoeia/usp32/pub/data/v32270/usp32nf27s0_c1112.html) - [USP \<2023\> Microbiological Attributes of Nonsterile Nutritional and Dietary Supplements](https://www.drugfuture.com/Pharmacopoeia/USP32/pub/data/v32270/usp32nf27s0_c2023.html) - [USP \<2021\> Microbial Enumeration Tests, Nutritional and Dietary Supplements](https://doi.usp.org/USPNF/USPNF_M99965_01_01.html) - USP \<2022\> Microbiological Procedures for Absence of Specified Microorganisms, Nutritional and Dietary Supplements - [USP \<905\> Uniformity of Dosage Units, FAQ](https://www.usp.org/frequently-asked-questions/uniformity-dosage-units) - [US 11,083,734, dexamethasone oral film (6-month 25/60 and 40/75 stability)](https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11083734) **Project-specific advice matters.** Formula feasibility, packaging, testing, claims, timing, and final quantities depend on the exact product. Use this guide to prepare better questions, then confirm the production plan for your project. [ODF and oral dissolving film manufacturing](https://stripworks.com/oral-dissolving-film-manufacturer)[Review StripWorks manufacturing capabilities](https://stripworks.com/oral-film-manufacturing-capabilities)[Quality and project controls](https://stripworks.com/quality-and-project-controls)[How StripWorks publishes buyer guidance](https://stripworks.com/editorial-standards)